Which laboratory tests are recommended for screening for hepatitis B virus infection and hepatitis C virus infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hepatitis B and C Screening Laboratory Tests

For hepatitis B screening, test HBsAg, anti-HBc, and anti-HBs; for hepatitis C screening, test anti-HCV antibody with reflex HCV RNA testing. 1, 2, 3, 4

Hepatitis B Virus Screening Tests

The 2023 CDC recommendations and 2025 EASL guidelines establish the standard screening panel 1, 2, 4:

Initial HBV Screening Panel (Three Tests):

  • HBsAg (Hepatitis B surface antigen) - Detects active infection (acute or chronic)
  • Anti-HBc (Hepatitis B core antibody, total) - Indicates past or current infection
  • Anti-HBs (Hepatitis B surface antibody) - Indicates immunity from vaccination or resolved infection

This three-test panel is recommended for universal screening of all adults aged ≥18 years at least once in their lifetime 1, 4. The combination provides complete information about infection status, immunity, and need for vaccination.

Interpretation Algorithm:

  • HBsAg positive = Active infection (proceed to HBV DNA quantification and HBeAg testing for disease staging) 2
  • Anti-HBc positive alone = Past infection or occult infection (consider HBV DNA testing if immunosuppression planned) 1
  • Anti-HBs positive alone = Immunity from vaccination 2
  • All negative = Susceptible, needs vaccination 5

Additional HBV Tests (Not for Initial Screening):

  • HBV DNA (quantitative) - Used after positive screening to assess viral load and guide treatment decisions 2
  • HBeAg/Anti-HBe - Used to define disease phase in confirmed infections 2
  • HBsAg quantitative - Used for treatment monitoring and defining prognosis 2

Hepatitis C Virus Screening Tests

The 2020 AASLD-IDSA guidelines establish the HCV screening approach 3:

Initial HCV Screening:

Anti-HCV antibody testing with reflex to HCV RNA PCR is the recommended screening strategy 3. This single blood draw approach prevents loss to follow-up.

Testing Algorithm:

  1. Anti-HCV antibody (laboratory-based or point-of-care)

    • If positive → Automatic reflex to HCV RNA testing
    • If negative → No current infection (unless recent exposure within 6 months or immunocompromised) 3
  2. HCV RNA by PCR (reflex test)

    • If positive → Active infection requiring treatment
    • If negative → Past resolved infection, no active disease 3

Important Caveats:

  • Window period consideration: If exposure occurred within the prior 6 months and anti-HCV is negative, perform HCV RNA testing or repeat anti-HCV testing ≥6 months post-exposure 3
  • Immunocompromised patients: Consider direct HCV RNA testing as antibody response may be impaired 3
  • Reinfection monitoring: In persons previously treated or spontaneously cleared, use HCV RNA directly (anti-HCV will remain positive) 3

Additional HCV Tests (After Positive Screening):

  • Quantitative HCV RNA - Document baseline viral load before treatment 3
  • HCV genotype - May be considered if it alters treatment recommendations (less critical with modern pangenotypic regimens) 3

Special Population Considerations

Dialysis Patients:

  • HBV: Screen with HBsAg, anti-HBs, and anti-HBc at baseline 5
    • Susceptible patients (all negative): Monthly HBsAg screening
    • Immune from vaccination (anti-HBs >10 IU/mL): Annual anti-HBs screening
    • Immune from prior infection (anti-HBs positive + anti-HBc positive): No further testing 5

Pregnant Women:

  • HBV: Universal screening recommended 6
  • HCV: Screen with anti-HCV; if positive, confirm with HCV RNA and obtain liver function tests, HCV genotype, and co-infection screening (HIV, HBV, syphilis) 7

Persons at Risk for HBV Reactivation:

  • Minimum screening: HBsAg and anti-HBc before immunosuppressive therapy 1
  • If either positive, obtain HBV DNA quantification 1

Co-infection Screening

When HBV is detected, screen for HDV (anti-HDV), HCV (anti-HCV), and HIV (anti-HIV1/2) 2. Similarly, when HCV is detected, screen for HBV and HIV 7.

Common Pitfalls to Avoid

  1. Do not screen with HBsAg alone - This misses past infections and immunity status, critical for vaccination decisions and reactivation risk assessment 1, 2

  2. Do not report anti-HCV positive as "active infection" - Always confirm with HCV RNA, as 15-25% spontaneously clear infection but remain antibody-positive 3

  3. Do not miss the window period - Recent HCV exposure (<6 months) may be antibody-negative but RNA-positive 3

  4. Do not use anti-HBs alone to guide HBV reactivation prophylaxis - The presence of anti-HBc is more important for determining reactivation risk 1

  5. Do not order HBeAg or HBV DNA as initial screening tests - These are for disease staging after confirmed infection, not for screening 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.